165529-95-3Relevant academic research and scientific papers
Structure-activity relationships in 3-oxo-1,4-benzodiazepine-2-acetic acid GPIIb/IIIa antagonists. The 2-benzazepine series
Miller, William H.,Ali, Fadia E.,Bondinell, William E.,Callahan, James F.,Calvo, Raul R.,Eggleston, Drake S.,Haltiwanger, R. Curtis,Huffman, William F.,Hwang, Shing-Mei,Jakas, Dalia R.,Keenan, Richard M.,Koster, Paul F.,Ku, Thomas W.,Kwon, Chet,Newlander, Kenneth A.,Nichols, Andrew J.,Parker, Michael F.,Samanen, James M.,Southall, Linda S.,Takata, Dennis T.,Uzinskas, Irene N.,Valocik, Richard E.,Vasko-Moser, Janice A.,Wong, Angela S.,Yellin, Tobias O.,Yuan, Catherine C. K.
, p. 2481 - 2486 (1996)
In an investigation of the contribution of N-1 to the binding, antiaggregatory, and oral activity in 3-oxo-1,4-benzodiazepine-2-acetic acid based GPIIb/IIIa antagonists, a series of 2-benzazepine analogs, wherein N-1 of the 1,4-benzodiazepine nucleus has
Bicyclic fibrinogen antagonists
-
, (2008/06/13)
This invention relates to compounds of the formulae: wherein A1is O, S, N—R1or CHR1; A4is N—R4or CHR4; R2is a sidechain containing an acid or ester group; R1, R4and R5are substituents such as H, alkyl and aryl alkyl, and R6is a sidechain containing a nitrogen group; and pharmaceutically acceptable salts thereof, which are effective for inhibiting platelet aggregation, pharmaceutical compositions for effecting such activity, and a method for inhibiting platelet aggregation.
